In 1983, the United States Congress passed legislation, known as the Orphan Drug Act, to incentivize companies to develop drugs for diseases with prevalence rates of less than 200,000 patients in the United States. Having such low prevalence rates, these diseases were defined in the Act as “rare diseases” or “orphan diseases”.
Prior to the passing […]
|
||||
|
|
||||
